| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
42,410,000 |
| Market
Cap: |
164.55(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.38 - $5.17 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Elevation Oncology is a precision oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Co.'s primary drug development candidate, seribantumab, is an Anti-HER3 monoclonal antibody and potential targeted therapy for solid tumors driven by neuregulin-1, a type of genomic alteration and oncogenic driver, and other receptor tyrosine-protein kinase erbB- (HER3), genomically defined cancers. Co. is also evaluating opportunities for pipeline expansion including prioritizing additional targeted therapy approaches in tumor types defined by genomic driver alterations.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
702,737 |
| Total Sell Value |
$0 |
$0 |
$0 |
$2,897,806 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ferra Joseph J Jr |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-03-16 |
4 |
D |
$4.39 |
$20,953 |
D/D |
(4,773) |
85,680 |
|
- |
|
| Ferra Joseph J Jr |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-03-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,562 |
90,453 |
|
- |
|
| Furlong Tammy |
CHIEF FINANCIAL OFFICER |
• – – |
2024-02-15 |
4 |
D |
$2.77 |
$1,116 |
D/D |
(403) |
797 |
|
- |
|
| Furlong Tammy |
CHIEF FINANCIAL OFFICER |
• – – |
2024-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,200 |
1,200 |
|
- |
|
| Ferra Joseph J Jr |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-12-16 |
4 |
D |
$0.51 |
$2,434 |
D/D |
(4,773) |
77,891 |
|
- |
|
| Ferra Joseph J Jr |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-12-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,563 |
82,664 |
|
- |
|
| Ferra Joseph J Jr |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-09-16 |
4 |
D |
$0.73 |
$3,475 |
D/D |
(4,773) |
70,101 |
|
- |
|
| Ferra Joseph J Jr |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-09-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,562 |
74,874 |
|
- |
|
| Clackson Timothy P |
|
– • – |
2023-09-01 |
4 |
GD |
$0.00 |
$0 |
D/D |
15,777 |
0 |
|
- |
|
| Ferra Joseph J Jr |
INTERIM CEO & CFO |
• – – |
2023-06-16 |
4 |
D |
$1.47 |
$7,016 |
D/D |
(4,773) |
62,312 |
|
- |
|
| Ferra Joseph J Jr |
INTERIM CEO & CFO |
• – – |
2023-06-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,563 |
67,085 |
|
- |
|
| Ferra Joseph J Jr |
INTERIM CEO & CFO |
• – – |
2023-03-16 |
4 |
D |
$2.35 |
$11,217 |
D/D |
(4,773) |
54,522 |
|
- |
|
| Ferra Joseph J Jr |
INTERIM CEO & CFO |
• – – |
2023-03-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,563 |
59,295 |
|
- |
|
| Ferra Joseph J Jr |
CHIEF FINANCIAL OFFICER |
• – – |
2022-12-16 |
4 |
D |
$0.95 |
$4,534 |
D/D |
(4,773) |
46,732 |
|
- |
|
| Ferra Joseph J Jr |
CHIEF FINANCIAL OFFICER |
• – – |
2022-12-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,562 |
51,505 |
|
- |
|
| Ferra Joseph J Jr |
CHIEF FINANCIAL OFFICER |
• – – |
2022-09-16 |
4 |
D |
$1.25 |
$5,966 |
D/D |
(4,773) |
38,943 |
|
- |
|
| Ferra Joseph J Jr |
CHIEF FINANCIAL OFFICER |
• – – |
2022-09-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,562 |
43,716 |
|
- |
|
| Ferra Joseph J Jr |
CHIEF FINANCIAL OFFICER |
• – – |
2022-06-16 |
4 |
D |
$1.26 |
$24,060 |
D/D |
(19,095) |
31,154 |
|
- |
|
| Ferra Joseph J Jr |
CHIEF FINANCIAL OFFICER |
• – – |
2022-06-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
50,249 |
50,249 |
|
- |
|
| Clackson Timothy P |
Director |
– • – |
2022-05-31 |
4 |
GD |
$0.00 |
$0 |
D/D |
31,553 |
15,777 |
|
- |
|
| Royston Aaron |
|
• • • |
2022-05-25 |
4 |
S |
$4.12 |
$2,897,806 |
D/D |
(702,737) |
1,905,430 |
|
70% |
|
| Cormorant Private Healthcare Fund Iii Lp |
10% Owner |
– – • |
2021-06-29 |
4 |
B |
$16.00 |
$4,000,000 |
I/I |
250,000 |
2,233,168 |
1.5 |
-32% |
|
| Cormorant Private Healthcare Fund Iii Lp |
10% Owner |
– – • |
2021-06-29 |
4 |
A |
$0.00 |
$0 |
I/I |
1,983,168 |
1,983,168 |
|
- |
|
| Royston Aaron |
10% Owner |
– – • |
2021-06-29 |
4 |
B |
$16.00 |
$10,000,000 |
D/D |
625,000 |
2,608,167 |
2.45 |
-32% |
|
| Royston Aaron |
10% Owner |
– – • |
2021-06-29 |
4 |
A |
$0.00 |
$0 |
D/D |
1,983,167 |
1,983,167 |
|
- |
|
33 Records found
|
|
Page 1 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.44 (10.19%) 
